Blood and Serum Se and Zn Levels and 10-Year Survival of Patients after a Diagnosis of Kidney Cancer
Elżbieta Złowocka-Perłowska,
Piotr Baszuk,
Wojciech Marciniak,
Róża Derkacz,
Aleksandra Tołoczko-Grabarek,
Marcin Słojewski,
Artur Lemiński,
Michał Soczawa,
Milena Matuszczak,
Adam Kiljańczyk,
Rodney J. Scott,
Jan Lubiński
Affiliations
Elżbieta Złowocka-Perłowska
Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, 70-204 Szczecin, Poland
Piotr Baszuk
Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, 70-204 Szczecin, Poland
Wojciech Marciniak
Read-Gene, Grzepnica, ul. Alabastrowa 8, 72-003 Dobra, Poland
Róża Derkacz
Read-Gene, Grzepnica, ul. Alabastrowa 8, 72-003 Dobra, Poland
Aleksandra Tołoczko-Grabarek
Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, 70-204 Szczecin, Poland
Marcin Słojewski
Department of Urology and Oncological Urology Clinic, Pomeranian Medical University, 70-204 Szczecin, Poland
Artur Lemiński
Department of Biochemical Research, Pomeranian Medical University, 70-204 Szczecin, Poland
Michał Soczawa
Department of Urology and Oncological Urology Clinic, Pomeranian Medical University, 70-204 Szczecin, Poland
Milena Matuszczak
Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, 70-204 Szczecin, Poland
Adam Kiljańczyk
Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, 70-204 Szczecin, Poland
Rodney J. Scott
School of Biomedical Sciences and Pharmacy, Centre for Information-Based Medicine, Hunter Medical Research Institute, University of Newcastle, Newcastle, NSW 2305, Australia
Jan Lubiński
Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, 70-204 Szczecin, Poland
The aim of the project was to evaluate the association between selenium (Se) and zinc (Zn) levels in blood and serum and kidney cancer mortality. In a prospective group of 284 consecutive, unselected patients with kidney cancer, we evaluated their 10-year survival rate in relation to the levels of Se and Zn in their blood and serum. Micronutrient levels were measured using an inductively coupled plasma mass spectrometer. Patients were divided into quartiles based on the distribution of Se and Zn levels arranged in increasing order. The following variables were taken into account in the multivariable models: age at diagnosis, gender, smoking, type of surgery and histopathological examination results. We observed a statistically significant association of all-cause mortality when subgroups with low blood selenium levels were compared to patients with high selenium levels (HR = 7.74; p p p = 0.016. For patients in the highest quartile of blood zinc/selenium ratio, compared to those in the lowest, the HR was 2.53; p = 0.008. Our study suggests that selenium levels, combined selenium and zinc levels (SeQI-ZnQI vs. SeQIV-ZnQIV) and zinc-to-selenium ratio (Zn/Se) are attractive targets for clinical trials aimed at improving the survival of kidney cancer patients.
